- Your Challenges
- Offerings
- News & Events
- Knowledge Center
- About Us
- Diagnostics
For In Vitro Diagnostic Use
Abbott RealTime IDH1 is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of mutations in the human isocitrate dehydrogenase-1 (IDH1) gene, which are oncogenic and can be found in acute myeloid leukemia (AML).
Abbott RealTime IDH1 is the only test approved by FDA as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVO® (ivosidenib).
Abbott RealTime IDH1 Package Insert (PDF 618KB)
Abbott RealTime IDH1 Package Insert Controls (PDF 491KB)
For Information Only - Not Controlled Copy
Abbott RealTime IDH1 is an in vitro polymerase chain reaction (PCR) assay for for the qualitative detection of single nucleotide variants (SNVs) coding five IDH1 R132 mutations (R132C, R132H, R132G, R132S, and R132L) in DNA extracted from human blood (EDTA) or bone marrow (EDTA).
Abbott RealTime IDH1 is for use with the Abbott m2000rt System.
Abbott RealTime IDH1 consists of two kits:
Intended Use
Abbott RealTime IDH1 is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs) coding five IDH1 R132 mutations (R132C, R132H, R132G, R132S, and R132L) in DNA extracted from human blood (EDTA) or bone marrow (EDTA).
Abbott RealTime IDH1 is for use with the Abbott m2000rt System.
Indications For Use
Abbott RealTime IDH1 is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVO® (ivosidenib).
ASSAY PROTOCOL
The Abbott RealTime IDH1 assay protocol includes the following steps:
A. Manual preparation (ie, DNA extraction) of samples (specimens and controls) using the Abbott mSample Preparation SystemDNA (List No. 06K12 24) reagents to isolate and purify sample DNA.
B. PCR assay setup using the sample eluates and the Abbott RealTime IDH1 Amplification Reagent Kit.
C. Amplification/detection on the Abbott m2000rt instrument.
Specimens for Abbott RealTime IDH1 are processed manually using Abbott mSample Preparation SystemDNA (List No. 06K12 24) reagents to isolate and purify sample DNA.
The Abbott RealTime IDH1 amplification reagents are combined into two amplification master mixes.
The purified DNA sample is combined with the master mixes in an Abbott 96-Well Optical Reaction Plate, and the plate is transferred to the Abbott m2000rt instrument for amplification and detection of IDH1 mutations.
Note: Per magnetic rack, a maximum of 12 samples (patient specimens and/or assay controls) can undergo DNA extraction. It is not recommended to perform DNA extraction in batch sizes that exceed 12 samples.
The specimen result is automatically reported on the Abbott m2000rt workstation at run completion. Assay controls are included within each run and are processed through the DNA extraction, amplification, and detection steps of the assay to assess run validity.
Software parameters specific to Abbott RealTime IDH1 are contained in an assay application specification file, which is loaded onto the Abbott m2000rt instrument by using a CD ROM disk.
Refer to the WARNINGS AND PRECAUTIONS section of this package insert for instructions before preparing samples.
LIMITATIONS OF THE ASSAY
Abbott RealTime IDH1 Assay is available at
Versiti
LabInfo@versiti.org
Call your Abbott Molecular Sales Representative
to know more or +1-800- 553-7042
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.